Minimizing IT, while improving glycemic control and body weight in type 2 diabetes, may reduce all-cause mortality,30 31 as there is a dose–response relationship between IT and all-cause mortality in type 2 diabetes.32 With concerns about the healthcare costs of insulin usage accompanying the expected increased type 2 diabetes prevalence,33 effective approaches, such as shown in our study, to stop IT are essential. The gene discussed is INS; the disease is type 2 diabetes mellitus.